YolTech Therapeutics Appoints Jessie Yeung as Chief Financial Officer

Shanghai, July 20, 2026 – YolTech Therapeutics today announced the appointment of Jessie Yeung as Chief Financial Officer. Ms. Yeung will lead growth-driving financial strategies and excel at bridging complex scientific narratives with rigorous capital market execution.

Prior to Yoltech, Jessie spent six years at Legend Biotech, serving as a key member of the leadership team that helped the company grow from from an early-stage startup into a 3,000-strong, global company. She served as Vice President of Finance and Investor Relations, and Interim CFO with responsibility of budgetary oversight, achieving profitability targets, long-range financial planning, and partnering with Johnson & Johnson to significantly reduce manufacturing costs for CARVYKTI®.

Throughout her tenure, Jessie was instrumental in executing Legend's capital markets strategy. Her Wall Street acumen helped craft the company's foundational investment thesis.

Jessie brings extensive biotech sector expertise to Yoltech. She previously served as Vice President of Investor Relations and Corporate Finance at Rocket Pharmaceuticals, where she led a $115 million public equity offering, and held biopharma equity research roles at Bank of America Merrill Lynch and Wells Fargo Securities. Her career foundation includes a formative ten-year tenure at JPMorgan spanning both the U.S. and Asian markets.

Jessie earned her MBA from Columbia Business School and a B.S. in Finance and Business Administration from Carnegie Mellon University.

"Jessie has helped build and grow leading biotechnology companies through critical stages of development," said Dr. Yuxuan Wu, Co-founder and Chief Executive Officer of YolTech Therapeutics. "Her experience in capital markets, corporate finance, and strategic execution will be invaluable as we expand our clinical programs, strengthen our global presence, and enter the next phase of YolTech's growth."

"I am excited to join YolTech at this important stage of its growth," said Ms. Yeung. "The company has built a compelling pipeline and a clear long-term vision. I look forward to partnering with the leadership team to support the company's continued clinical progress, strengthen its financial foundation, and create long-term value for patients and shareholders."